[A24-58] Pembrolizumab (gastric and gastro-oesophageal junction adenocarcinoma, HER2-positive) – Addendum to Project A24-01
Last updated 20.06.2024
Project no.:
A24-58
Commission:
Commission awarded on 07.05.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma whose tumours express PD-L1 (CPS ≥ 1); first-line treatment
Unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A24-58_en
| Project no. | Title | Status |
|---|---|---|
| A24-01 | Pembrolizumab (gastric or gastro-oesophageal junction adenocarcinoma, HER2-positive) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-06-20 A G-BA decision was published.